Opportunities and Future Growth of the CDMO Market

Dennis Brandl, President, at BR&L Consulting, spoke with BioPharm International about what should be expected when transitioning from paper to EBR.

This podcast explores the challenges of and the progress made so far by the biopharma industry toward alternative drug delivering methods for biologic drugs.

A conversation with Armand Keating, the Epstein Chair in Cell Therapy and Transplantation at the University of Toronto prior to his presentation at Bio 2013

Learn Morewww.bio-rad.com/fluvaccine